Clinical Research Directory

Inclusion Criteria: * Patient must provide written informed consent prior to participating in this protocol * Patient must have been prescribed TECELRA® * Patient's commercially manufactured product does not meet the commercial release specification * Repeat manufacture is not feasible or is not clinically appropriate per Investigator assessment in consultation with per consultation with USWM CT * Repeat leukapheresis is not feasible or is not clinically appropriate per Investigator assessment * The Investigator has confirmed a favorable benefit:risk profile, following sponsor evaluation of the NC afami-cel, and deems proceeding with treatment under this EAP is in the best interest of the patient * Patient deemed medically fit and stable to receive NC afami-cel per Investigator assessment * Female patients with reproductive potential must have a negative serum or urine pregnancy test within 7 days of initiating lymphodepleting chemotherapy Exclusion Criteria: * Patient has contraindication(s) as per the TECELRA® USPI * Do not use TECELRA® in adults who are heterozygous or homozygous for HLA-A\*02:05P